Innate Pharma Unveils Promising Cancer Therapies at EHA
Innate Pharma's Four Abstracts With Innate's Drug Candidates Accepted For The European Association Of Hematology 2024 Congress
Two abstracts on SAR443579 (IPH6101), ANKET platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancerTwo abstracts on IPH6501, Inna
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate's drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Earnings Call Summary | Innate Pharma(IPHA.US) Q1 2024 Earnings Conference
The following is a summary of the Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript:Financial Performance:Innate Pharma has a firm cash status with about EUR115 million in cash as of the end
Innate Pharma S.A. Advances Oncology Pipeline
6-K: Report of foreign private issuer (related to financial reporting)
Innate Pharma Reported Q1 Revenue Of €6.6M Down From €26M YoY; Cash Position Of €113.9M
First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 t
Press Release: Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results -- First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Innate Pharma's NK Cell Engager Enters Phase 2 Trials
Innate Pharma Announces Upcoming Annual General Meeting
Innate Pharma S.A., a clinical-stage biotechnology company, has announced its Annual General Meeting (AGM) scheduled for May 23, 2024, at its Marseille headquarters. Shareholders are invited to participate in the AGM and a guided tour of the company’s laboratories, with preparatory documents available on Innate’s website.
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio
Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients
Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of Shareholders ("AGM") at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de
HC Wainwright & Co. : The Innate Pharma (IPHA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $11.50.
HC Wainwright & Co. : The Innate Pharma (IPHA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $11.50.
Innate Pharma: A Strong Buy on IPH45's Promising Data and Solid Financial Projections
Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report) and keeping the price target at $11.50.
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
No Data